عرض بسيط للتسجيلة

المؤلفAl-Maslamani, Muna
المؤلفElmagboul, Emad Bashier Ibrahim
المؤلفPuthiyottil, Aslam
المؤلفChemaitelly, Hiam
المؤلفVarghese, Manoj Kizhakkepeedikayil
المؤلفAl Romaihi, Hamad Eid
المؤلفAl-Thani, Mohamed H.
المؤلفAl Khal, Abdullatif
المؤلفUnemo, Magnus
المؤلفAbu-Raddad, Laith J.
تاريخ الإتاحة2023-07-24T10:35:25Z
تاريخ النشر2022-03-02
اسم المنشورPLoS ONE
المعرّفhttp://dx.doi.org/10.1371/journal.pone.0264737
الاقتباسAl-Maslamani, M., Elmagboul, E. B. I., Puthiyottil, A., Chemaitelly, H., Varghese, M. K., Al Romaihi, H. E., ... & Abu-Raddad, L. J. (2022). First characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017–2020. Plos one, 17(3), e0264737.
الرقم المعياري الدولي للكتاب1932-6203
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85125611676&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/46237
الملخصLimited data are available regarding antimicrobial resistance in Neisseria gonorrhoeae strains circulating in WHO Eastern Mediterranean Region (EMR). We investigated the antimicrobial susceptibility/resistance of N. gonorrhoeae isolates to five antimicrobials (ceftriaxone, azithromycin, ciprofloxacin, tetracycline, and benzylpenicillin) currently or previously used for gonorrhoea treatment in Qatar, 2017-2020. Minimum inhibitory concentrations (MICs; mg/L) of antimicrobials were determined using Etest on gonococcal isolates collected during January 1, 2017-August 30, 2020 at Hamad Medical Corporation, a national public healthcare provider. During 2017-2020, resistance in isolates from urogenital sites of 433 patients was 64.7% (95% CI: 59.5-69.6%; range: 43.9-78.7%) for ciprofloxacin, 50.7% (95% CI: 45.3-56.1%; range: 41.3-70.4%) for tetracycline, and 30.8% (95% CI: 26.3- 35.6%; range: 26.7-35.8%) for benzylpenicillin. Percentage of isolates non-susceptible to azithromycin was 4.1% (95% CI: 2.0-7.4%; range: 2.7-4.8%) and all (100%) isolates were susceptible to ceftriaxone. Two (1.6%) isolates from 2019 and one (2.2%) isolate from 2020 had high-level resistance to azithromycin (MIC≥256 mg/L). Overall, 1.0% (4/418) of isolates had a ceftriaxone MIC of 0.25 mg/L, which is at the ceftriaxone susceptibility breakpoint (MIC≥0.25 mg/L). Treatment with ceftriaxone 250 mg plus azithromycin 1 g can continuously be recommended for gonorrhoea therapy in Qatar. Continued quality-assured gonococcal AMR surveillance is warranted in EMR.
اللغةen
الناشرPublic Library of Science
الموضوعantibiotic resistance
WHO Eastern Mediterranean Region
Anti-Bacterial Agents
العنوانFirst characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017-2020
النوعArticle
رقم العدد3
رقم المجلد17
dc.accessType Open Access


الملفات في هذه التسجيلة

Thumbnail

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة